TransCode Therapeutics, Inc. - Common Stock (RNAZ)
14.80
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 9th, 4:39 AM EDT
Detailed Quote
Previous Close
14.80
Open
-
Bid
13.09
Ask
13.54
Day's Range
N/A - N/A
52 Week Range
6.149 - 739.20
Volume
3,381
Market Cap
12.34M
PE Ratio (TTM)
-0.2755
EPS (TTM)
-53.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
338,798
Chart
About TransCode Therapeutics, Inc. - Common Stock (RNAZ)
Transcode Therapeutics Inc is a biotechnology company focused on developing innovative RNA-based therapeutics aimed at treating cancer and other serious diseases. The company specializes in harnessing the potential of RNA to create targeted therapies that can address the underlying mechanisms of diseases, particularly in oncology. By leveraging its proprietary technology platforms, Transcode aims to enhance the precision of cancer treatments and improve patient outcomes, while also exploring applications in other therapeutic areas. The company's commitment to advancing RNA therapeutics positions it at the forefront of cutting-edge research in the life sciences field. Read More
In today’s MAGA Stocks Undercard lineup, a select group of small-cap innovators are reshaping the landscapes of social media, biotech, and blockchain technology. These companies—each positioned at the forefront of next-generation disruption—are demonstrating renewed investor confidence and sector-wide momentum heading into Q4.
TransCode Therapeutics (NASDAQ: RNAZ) announced it has entered into a definitive agreement to acquire Polynoma LLC, a privately held immuno-oncology company developing seviprotimut-L, a late-stage polyvalent shed antigen vaccine for the adjuvant treatment of stage IIB and IIC melanoma. Concurrent with the acquisition, TransCode secured a $25 million investment from CK Life Sciences Int’l (Holdings) Inc. to fund its lead microRNA candidate, TTX-MC138, through a Phase 2 clinical trial. Philippe Calais, PharmD, PhD, was appointed Chief Executive Officer, succeeding Interim CEO Tom Fitzgerald, who returns to his role as CFO. “This acquisition allows us to create a unique and broader oncology pipeline with Phase 3-ready seviprotimut-L and our TTX-MC138 program,” said Dr. Calais. “Together, these assets position TransCode to deliver meaningful therapeutic advances for patients battling melanoma and metastatic disease.”
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences and other prestigious institutions underscores his impact on the field. TransCode leaders praised the addition as a strategic enhancement to the company’s RNA-targeted cancer therapy programs.
TransCode Therapeutics (NASDAQ: RNAZ), has appointed Dr. Phillip D. Zamore, a leading figure in RNA interference (RNAi) research and co-founder of Alnylam Pharmaceuticals, to its Scientific Advisory Board. Dr. Zamore, currently Chair of the RNA Therapeutics Institute at UMass Chan Medical School, is renowned for his foundational work in RNA biology and gene silencing mechanisms. His election to the National Academy of Sciences and other prestigious institutions underscores his impact on the field. TransCode leaders praised the addition as a strategic enhancement to the company’s RNA-targeted cancer therapy programs.
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
TransCode Therapeutics (NASDAQ: RNAZ) announced that the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138 has been dosed, with 15 patients now treated across four dose levels. The Safety Review Committee approved expanded enrollment and noted no significant toxicities or disease progression to date. Ten patients remain on study, with the longest treated showing stable disease after seven cycles. Early PK/PD data confirm target engagement and support advancing to the Phase 1b dose expansion stage.
TransCode Therapeutics (NASDAQ: RNAZ), the RNA oncology company focused on developing RNA therapeutics to treat cancer, will implement a 1-for-28 reverse stock split effective May 15, 2025, at 12:01 a.m. EDT. Shares will begin trading on a split-adjusted basis that same day under the existing ticker, “RNAZ.” The move, approved by shareholders and the board, aims to raise the company’s per-share price to maintain compliance with Nasdaq’s minimum bid price requirement. Post-split, TransCode’s outstanding common stock will decrease from approximately 23.3 million to about 833,620 shares. No fractional shares will be issued; instead, amounts will be rounded up to the nearest whole share. Vstock Transfer LLC will act as the exchange agent. The new CUSIP number will be 89357L 501.
